IN2014MN01546A - - Google Patents

Info

Publication number
IN2014MN01546A
IN2014MN01546A IN1546MUN2014A IN2014MN01546A IN 2014MN01546 A IN2014MN01546 A IN 2014MN01546A IN 1546MUN2014 A IN1546MUN2014 A IN 1546MUN2014A IN 2014MN01546 A IN2014MN01546 A IN 2014MN01546A
Authority
IN
India
Prior art keywords
compounds
formula
diastereoisomers
stereoisomers
prevention
Prior art date
Application number
Other languages
English (en)
Inventor
Somesh Sharma
Alan Hatfield
Shivani Acharya
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of IN2014MN01546A publication Critical patent/IN2014MN01546A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IN1546MUN2014 2012-01-13 2013-01-11 IN2014MN01546A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586428P 2012-01-13 2012-01-13
PCT/IB2013/050263 WO2013105056A1 (en) 2012-01-13 2013-01-11 Pyrrolidine- substituted flavone derivatives for prevention or treatment of oral mucositis

Publications (1)

Publication Number Publication Date
IN2014MN01546A true IN2014MN01546A (enExample) 2015-05-08

Family

ID=47748672

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1546MUN2014 IN2014MN01546A (enExample) 2012-01-13 2013-01-11

Country Status (6)

Country Link
US (2) US20140348950A1 (enExample)
EP (1) EP2802323B1 (enExample)
AR (1) AR090052A1 (enExample)
IN (1) IN2014MN01546A (enExample)
TW (1) TW201338774A (enExample)
WO (1) WO2013105056A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733929T3 (es) 2013-07-12 2019-12-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
KR101209397B1 (ko) 2006-06-21 2012-12-06 피라말 라이프 사이언시스 리미티드 증식성 질환 치료용 광학이성적으로 순수한, 증식성 질환 치료용 플라본 유도체 및 이의 제조방법
WO2008007169A1 (en) 2006-07-07 2008-01-17 Piramal Life Sciences Limited An enantioselective synthesis of pyrrolidine-substituted flavones
TWI461194B (zh) * 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑

Also Published As

Publication number Publication date
WO2013105056A1 (en) 2013-07-18
AR090052A1 (es) 2014-10-15
EP2802323A1 (en) 2014-11-19
TW201338774A (zh) 2013-10-01
EP2802323B1 (en) 2016-08-10
US20140348950A1 (en) 2014-11-27
US20170071908A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
ZA202003554B (en) 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
NZ708593A (en) Novel pyrazole derivative
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
PH12016502355A1 (en) Pharmaceutical composition
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
NZ708382A (en) Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents
PH12015502159A1 (en) Chemical entities
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
PH12014500386A1 (en) Combination treatment for hepatitis c
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX369952B (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1.
MX2015011614A (es) Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia.
PH12016502353A1 (en) Pharmaceutical composition
PH12016502352A1 (en) Pharmaceutical composition
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
TR201819805T4 (tr) Flavaglin türevleri̇.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2015009176A (es) Derivados de triazola antivirales.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
IN2014MN01546A (enExample)